VA
STRO icon

Verdad Advisers’s Sutro Biopharma STRO Stock Holding History

Verdad Advisers’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
+6,400
New +$200K 0.2% 149

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Verdad Advisers's STRO Position: Q2 2026 in Review

Verdad Advisers opened a new position in Sutro Biopharma (STRO) in Q2 2026: 6,400 shares worth $212K. The stake represents 0.2% of the portfolio and ranks #149 among its holdings.

100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Verdad Advisers held 6,400 shares of Sutro Biopharma worth $212K as of Q2 2026.
  • Sutro Biopharma was a new Verdad Advisers position in Q2 2026.
  • Sutro Biopharma made up 0.2% of Verdad Advisers's portfolio in Q2 2026, its #149 holding.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.